Sun Pharmaceutical Industries Limited will hold its 34th Annual General Meeting on Friday, July 31, 2026, at 4:00 P.M. IST via video conferencing. The Board of Directors has recommended a final dividend of ₹5 per equity share of face value ₹1 each for the financial year 2025-26. This dividend is subject to the approval of members at the ensuing AGM.

The company has fixed Tuesday, July 7, 2026, as the record date to determine the members eligible to receive the dividend. Shareholders holding shares as on this date will receive the payment electronically, provided their bank details are updated with the depository participant or the company's Registrar and Transfer Agent (RTA), MUFG Intime India Private Limited.

Members holding shares in physical form must update their KYC details, including PAN, contact details, nomination, bank account details, and specimen signature, in accordance with a SEBI circular dated June 10, 2024. Failure to meet these KYC requirements, excluding the non-submission of a choice of nomination, will result in the inability to receive dividends.

The Notice of the 34th AGM along with the Annual Report for the financial year 2025-26 will be sent electronically to members whose email addresses are registered with the RTA or depositories. These documents will also be available on the company's website and the websites of BSE Limited and National Stock Exchange of India Limited.

Members will have the opportunity to cast their votes remotely on the business set forth in the Notice through remote e-voting. The facility for e-voting will also be provided at the AGM for members attending the meeting who have not cast their votes remotely. Central Depository Services (India) Limited (CDSL) has been appointed as the agency for providing the e-voting facility.

Sun Pharmaceutical Industries Limited has agreed to acquire 100% of the outstanding shares of Innovcare Lifesciences Private Limited for a cash consideration of approximately ₹271.2 crore. The acquisition is a strategic investment intended to strengthen the product portfolio of Sun Pharmaceutical Industries Limited . The transaction is expected to be completed on or before 31 July 2026.

Innovcare Lifesciences, a Mumbai-based company incorporated on 21 July 2014, is engaged in the marketing, distribution, and sale of pharmaceutical drugs, nutraceutical, and cosmeceutical products. The company operates solely within India and reported revenue from operations of ₹94.06 crore for FY 2025-26.

The acquisition is not a related party transaction, and the promoter or promoter group of Sun Pharma does not hold any interest in Innovcare Lifesciences. No governmental or regulatory approvals are required for the completion of this transaction, and the consideration will be paid entirely in cash.

Financial Performance of Innovcare Lifesciences

Innovcare Lifesciences has demonstrated consistent revenue growth over the past three financial years, as detailed below:

This acquisition aligns with Sun Pharma's strategy to expand its presence in the pharmaceutical and healthcare sectors.